BI Asset Management Fondsmaeglerselskab A S Purchases 110,415 Shares of Merck & Co., Inc. $MRK

BI Asset Management Fondsmaeglerselskab A S grew its position in Merck & Co., Inc. (NYSE:MRK) by 8.9% during the fourth quarter, HoldingsChannel.com reports. The fund owned 1,357,299 shares of the company’s stock after acquiring an additional 110,415 shares during the quarter. Merck & Co., Inc. comprises 1.2% of BI Asset Management Fondsmaeglerselskab A S’s investment portfolio, making the stock its 12th biggest position. BI Asset Management Fondsmaeglerselskab A S’s holdings in Merck & Co., Inc. were worth $141,523,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in MRK. Chesapeake Wealth Management raised its position in shares of Merck & Co., Inc. by 0.6% in the 4th quarter. Chesapeake Wealth Management now owns 14,740 shares of the company’s stock worth $1,552,000 after acquiring an additional 87 shares in the last quarter. Syverson Strege & Co raised its position in shares of Merck & Co., Inc. by 2.2% in the 4th quarter. Syverson Strege & Co now owns 4,142 shares of the company’s stock worth $436,000 after acquiring an additional 90 shares in the last quarter. Westside Investment Management Inc. raised its position in shares of Merck & Co., Inc. by 3.1% in the 4th quarter. Westside Investment Management Inc. now owns 3,142 shares of the company’s stock worth $331,000 after acquiring an additional 93 shares in the last quarter. Valued Wealth Advisors LLC raised its position in shares of Merck & Co., Inc. by 26.9% in the 4th quarter. Valued Wealth Advisors LLC now owns 444 shares of the company’s stock worth $47,000 after acquiring an additional 94 shares in the last quarter. Finally, Intrua Financial LLC raised its position in shares of Merck & Co., Inc. by 1.1% in the 4th quarter. Intrua Financial LLC now owns 8,604 shares of the company’s stock worth $906,000 after acquiring an additional 96 shares in the last quarter. Institutional investors own 76.07% of the company’s stock.

Wall Street Analysts Forecast Growth

MRK has been the subject of several recent research reports. Guggenheim boosted their price target on Merck & Co., Inc. from $122.00 to $140.00 and gave the stock a “buy” rating in a research report on Friday, February 6th. JPMorgan Chase & Co. upped their target price on Merck & Co., Inc. from $125.00 to $135.00 and gave the company an “overweight” rating in a research report on Monday, April 6th. UBS Group upped their target price on Merck & Co., Inc. from $130.00 to $145.00 and gave the company a “buy” rating in a research report on Monday, April 13th. Royal Bank Of Canada reaffirmed an “outperform” rating and set a $142.00 target price on shares of Merck & Co., Inc. in a research report on Monday, March 30th. Finally, Barclays started coverage on Merck & Co., Inc. in a research report on Friday, February 20th. They set an “overweight” rating and a $140.00 target price on the stock. One equities research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and seven have issued a Hold rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $128.18.

Merck & Co., Inc. News Summary

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck reached a settlement of more than $50 million to resolve over 200 Gardasil-related lawsuits, removing a significant legal overhang and helping investors refocus on the company’s core business and pipeline. Merck Gardasil Settlement Eases Legal Overhang And Refocuses Investor Attention
• Positive Sentiment: Merck recently broke above both its 20-day and 50-day moving averages, a technical signal that traders often view as a sign of improving short-term momentum. Merck (MRK) Recently Broke Out Above the 20-Day Moving Average
• Positive Sentiment: Merck’s oncology franchise continues to draw attention after ASCO 2026 updates highlighted Keytruda’s strength in solid tumors and other pipeline assets aimed at offsetting future exclusivity pressure. ASCO26: Solid tumour data readouts outline Merck & Co’s oncology prowess
• Positive Sentiment: Merck’s collaboration with Moderna on a personalized mRNA cancer vaccine also got a boost from positive long-term data disclosed by Moderna, reinforcing investor interest in the partnership. Why Is Moderna (MRNA) Stock Rocketing Higher Today
• Neutral Sentiment: Merck’s conference appearance and oncology strategy update likely kept investor focus on the pipeline, but the items available do not indicate a major new catalyst beyond ongoing progress. Merck & Co., Inc. (MRK) Discusses Oncology Strategy and Program Update With Focus on Clinical Progress and Pipeline Diversification – Slideshow

Merck & Co., Inc. Stock Performance

Shares of MRK stock opened at $121.05 on Friday. The company has a market capitalization of $298.96 billion, a P/E ratio of 34.10, a P/E/G ratio of 2.70 and a beta of 0.21. The business’s 50 day moving average is $116.55 and its two-hundred day moving average is $112.39. The company has a current ratio of 1.30, a quick ratio of 1.06 and a debt-to-equity ratio of 1.02. Merck & Co., Inc. has a 12-month low of $76.66 and a 12-month high of $125.14.

Merck & Co., Inc. (NYSE:MRK) last issued its quarterly earnings results on Thursday, April 30th. The company reported ($1.28) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.47) by $0.19. The company had revenue of $16.29 billion for the quarter, compared to the consensus estimate of $15.85 billion. Merck & Co., Inc. had a return on equity of 27.55% and a net margin of 13.59%.Merck & Co., Inc.’s revenue for the quarter was up 4.9% on a year-over-year basis. During the same quarter in the prior year, the business posted $2.22 earnings per share. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. Analysts expect that Merck & Co., Inc. will post 5.17 EPS for the current fiscal year.

Merck & Co., Inc. Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, July 8th. Shareholders of record on Monday, June 15th will be given a dividend of $0.85 per share. The ex-dividend date is Monday, June 15th. This represents a $3.40 dividend on an annualized basis and a yield of 2.8%. Merck & Co., Inc.’s dividend payout ratio is currently 95.77%.

Merck & Co., Inc. Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.